PURPOSE: To report the clinical outcome of treatment using real-time tumor tracking for 70 patients with inoperable stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Seventy inoperable patients with peripherally located early-stage NSCLC were treated with 45 or 60 Gy in three fractions using CyberKnife. Pathology was available in 51% of patients. Thirty-nine patients had a T1-tumor and 31 had a T2-tumor. Markers were placed using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk of pneumothorax. RESULTS: The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared to 78% for patients treated with a total dose of 45 Gy (p=0.197). All local recurrences (n=4) occurred in patients with T2-tumors. Overall survival for the whole group at two years was 62% and the cause specific survival was 85%. The median follow-up was 15 months. Grade 3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade 3 toxicity occurred in 7 patients (10%). No grade > or = 4 toxicity occurred. CONCLUSION: Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in three fractions for NSCLC patients treated with the real-time tumor tracking. Toxicity was low.
PURPOSE: To report the clinical outcome of treatment using real-time tumor tracking for 70 patients with inoperable stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Seventy inoperable patients with peripherally located early-stage NSCLC were treated with 45 or 60 Gy in three fractions using CyberKnife. Pathology was available in 51% of patients. Thirty-nine patients had a T1-tumor and 31 had a T2-tumor. Markers were placed using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk of pneumothorax. RESULTS: The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared to 78% for patients treated with a total dose of 45 Gy (p=0.197). All local recurrences (n=4) occurred in patients with T2-tumors. Overall survival for the whole group at two years was 62% and the cause specific survival was 85%. The median follow-up was 15 months. Grade 3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade 3 toxicity occurred in 7 patients (10%). No grade > or = 4 toxicity occurred. CONCLUSION: Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in three fractions for NSCLCpatients treated with the real-time tumor tracking. Toxicity was low.
Authors: Vincent Caillet; Ricky O'Brien; Douglas Moore; Per Poulsen; Tobias Pommer; Emma Colvill; Amit Sawant; Jeremy Booth; Paul Keall Journal: Med Phys Date: 2019-03-04 Impact factor: 4.071
Authors: Hannah Bainbridge; Ahmed Salem; Rob H N Tijssen; Michael Dubec; Andreas Wetscherek; Corinne Van Es; Jose Belderbos; Corinne Faivre-Finn; Fiona McDonald Journal: Transl Lung Cancer Res Date: 2017-12
Authors: Saloomeh Vahdat; Eric K Oermann; Sean P Collins; Xia Yu; Malak Abedalthagafi; Pedro Debrito; Simeng Suy; Shadi Yousefi; Constanza J Gutierrez; Thomas Chang; Filip Banovac; Eric D Anderson; Giuseppe Esposito; Brian T Collins Journal: J Hematol Oncol Date: 2010-02-04 Impact factor: 17.388